114 related articles for article (PubMed ID: 9076482)
1. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():20-6. PubMed ID: 9076482
[TBL] [Abstract][Full Text] [Related]
2. Treatment of carcinoma in situ of the urinary bladder with bropirimine.
Witjes JA
Eur Urol; 1997; 31 Suppl 1():27-30. PubMed ID: 9076483
[TBL] [Abstract][Full Text] [Related]
3. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.
Sarosdy MF; Manyak MJ; Sagalowsky AI; Belldegrun A; Benson MC; Bihrle W; Carroll PR; Ellis WJ; Hudson MA; Sharkey FE
Urology; 1998 Feb; 51(2):226-31. PubMed ID: 9495702
[TBL] [Abstract][Full Text] [Related]
4. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.
Sarosdy MF; Lowe BA; Schellhammer PF; Lamm DL; Graham SD; Grossman HB; See WA; Peabody JO; Moon TD; Flanigan RC; Crawford ED; Morganroth J
Urology; 1996 Jul; 48(1):21-7. PubMed ID: 8693646
[TBL] [Abstract][Full Text] [Related]
5. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.
Witjes WP; König M; Boeminghaus FP; Hall RR; Schulman CC; Zurlo M; Fittipaldo A; Riggi M; Debruyne FM
Eur Urol; 1999 Dec; 36(6):576-81. PubMed ID: 10559611
[TBL] [Abstract][Full Text] [Related]
6. [Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2049-53. PubMed ID: 10584570
[TBL] [Abstract][Full Text] [Related]
7. Bropirimine immunotherapy of upper urinary tract carcinoma in situ.
Sarosdy MF; Pisters LL; Carroll PR; Benson MC; Moon TD; Lamm DL; Hudson MA; Lerner SP; Koch MO; Schellhammer PF
Urology; 1996 Jul; 48(1):28-32. PubMed ID: 8693647
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of oral bropirimine in superficial bladder cancer.
Sarosdy MF; Lamm DL; Williams RD; Moon TD; Flanigan RC; Crawford ED; Wilks NE; Earhart RH; Merritt JA
J Urol; 1992 Jan; 147(1):31-3. PubMed ID: 1729546
[TBL] [Abstract][Full Text] [Related]
9. [Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):77-85. PubMed ID: 9020949
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Sarosdy MF; Tangen CM; Weiss GR; Nestok BR; Benson MC; Schellhammer PF; Sagalowsky AI; Wood DP; Crawford ED
Urol Oncol; 2005; 23(6):386-9. PubMed ID: 16301114
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
13. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
14. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
15. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy.
Kim SJ; You D; Jeong IG; Song C; Hong B; Kim CS; Ahn H; Hong JH
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2131-2140. PubMed ID: 31227894
[TBL] [Abstract][Full Text] [Related]
17. Current state of immunotherapy for bladder cancer.
Kassouf W; Kamat AM
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1037-46. PubMed ID: 15606331
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
